SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals

Great expectations are placed in vaccines against COVID-19 to control the pandemic. We reviewed the antibody titres in a cohort of healthcare workers (HCWs) vaccinated with BNT162b2 to assess the influence of a previous infection on them. We stratified the results according to the individual history...

Descripción completa

Detalles Bibliográficos
Autores principales: Lombardi, Andrea, Consonni, Dario, Oggioni, Massimo, Bono, Patrizia, Renteria, Sara U., Piatti, Alessandra, Pesatori, Angela C., Castaldi, Silvana, Muscatello, Antonio, Riboldi, Luciano, Ceriotti, Ferruccio, Bandera, Alessandra, Gori, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285930/
https://www.ncbi.nlm.nih.gov/pubmed/34293641
http://dx.doi.org/10.1016/j.jiph.2021.07.005
Descripción
Sumario:Great expectations are placed in vaccines against COVID-19 to control the pandemic. We reviewed the antibody titres in a cohort of healthcare workers (HCWs) vaccinated with BNT162b2 to assess the influence of a previous infection on them. We stratified the results according to the individual history of nasopharyngeal swab (NPS) and symptoms. Among 3475 HCWs the highest titres were recorded among those infected more than 6 months before vaccination, independently of symptoms, followed by those infected less than 6 months before vaccination, especially in those with symptoms, and by uninfected HCWs. Vaccination with BNT162b2 can boost immunity acquired through infection, particularly in those infected more than 6 months before vaccination.

Ejemplares similares